ABP 215

• Description :

  ABP 215 (Bevacizumab-awwb), a Bevacizumab (HY-P9906) biosimilar, is a humanized IgG1 monoclonal antibody targeting VEGFA. ABP 215 has anticancer effects, and can be used metastatic colorectal cancer (mCRC) research[1][2].

• UNSPSC :

  12352203

• Target :

  VEGFR

• Type :

  Inhibitory Antibodies

• Related Pathways :

  Protein Tyrosine Kinase/RTK

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/abp-215.html

• Solubility :

  10 mM in DMSO

• Smiles :

  [ABP215]

• References & Citations :

  [1]Neungseon Seo, et al. Analytical and functional similarity of Amgen biosimilar ABP 215 to bevacizumab. MAbs. 2018 May/Jun;10 (4) :678-691. |[2]Whitney Rhodes, et al. Real-world use of bevacizumab-awwb, a bevacizumab biosimilar, in US patients with metastatic colorectal cancer. Future Oncol. 2021 Dec;17 (36) :5119-5127.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Inhibitory Antibodies

• Clinical Information :

  Phase 3

• CAS Number :

  [1438851-35-4]